










TABLE OF CONTENTS Table of Contents 2 Land Acknowledgement ______ 3 Message From the Mayor Message from the CSTM ______5 Message from Canadian Blood Services _______ 7 Message from Héma-Québec 8 Registration Information______9 SJCC Floor Plan level 2 10 SJCC Floor Plan Level 3 ______ 11 Conference at a Glance ______ 12 Thursday May 29 Workshops _______ 12 Friday May 30 Scientific Program _______ 13 Saturday May 31 Scientific Program _______ 14 Sunday June 1 Scientific Program 15 Waterford River T'railway 5 KM Fun Run/Walk Map ______ 16 Keynote Speaker 17 CSTM Awards ______ 18 CSTM Blum Award ______ 18 QuidelOrtho Award _______19 CSTM Buchanan Award ______ 20 Canadian Blood Services Dana Devine award ________21 Bursaries _____ 22 2025 Grifols Laboratory Technologist Bursary in Honour of Pat Letendre _____ 22 2025 CSL Behring Nursing Bursary ______ 22 2025 CSTM Speaker Legacy Bursary ______ 22 ______ 23 Exhibitors List and Booth List ______ 28 Thank You to our Exhibitors _____ ______29 Thank you to our Sponsors and Partners 30 Platinum Sponsors ______ 30 Silver Sponsors _____ 31 Bronze Sponsors 31 ______ 31 Detailed Scientific Program _____ ____ 32 Visiting St. John's 43 CSTM 2025 Conference Committee Members ______ 46 Thank You _____ 47 CSTM 2026 – Hamilton _____ 48

LAND ACKNOWLEDGEMENT

We respectfully acknowledge the province of Newfoundland and Labrador as the ancestral homelands of many diverse populations of Indigenous people who have contributed to 9,000 years of history including the Beothuk on the Island of Newfoundland. Today, this province is home to diverse populations of Indigenous and other people. We also acknowledge, with respect, the diverse histories and cultures of the Mi'kmaq, Innu, and Inuit.



Message from the Mayor

As the Mayor of St. John's, Newfoundland and Labrador, it is my great pleasure to welcome you to the CSTM Annual Scientific Meeting, taking place from May 29 to June 1, 2025, in our vibrant city.



Hosting this conference in different regions each year promotes continuous education, collaboration, and networking within the transfusion medicine community across Canada. We are honored to have been chosen as the host city for the 2025 meeting and look forward to welcoming all participants to St. John's. We hope you take the opportunity to experience our intriguing blend of history, culture and hospitality while you are here.

St. John's is an exciting city with many wonderful places to eat, shop, relax and explore and it is our hope that you get to experience all that we have to offer while you are here for your Conference. From the beautiful downtown to our bustling business centres, St. John's has much to offer. Be sure to take in one of our beautiful and historic parks or museums, visit iconic Signal Hill or take a trip out to Cape Spear or Petty Harbour - there's so much to see and do!

I wish you a successful and enriching conference.

Danny Breen

Mayor of St. John's

ST. JOHN'S

MESSAGE FROM THE CSTM



Dear CSTM members,

On behalf of the CSTM board of directors, it is my great pleasure to welcome you to the 2025 CSTM Annual Scientific Conference, taking place from May 29-June1 at St. John's Convention Centre!

We are thrilled to have you join us for this exciting event, 'No Lab is an Island', where industry leaders, experts, and passionate professionals from across Canada will come together to share knowledge, ideas, and experiences. Our aim is to provide a platform for thoughtful discussions, networking opportunities, and innovative insights that will inspire new ways of thinking and foster meaningful connections in the field of Transfusion Medicine

Over the next few days, you will have the opportunity to attend a wide range of sessions, workshops, and our keynote speech, all designed to offer both practical and visionary perspectives on the latest trends and developments in Transfusion Medicine. We encourage you to take full advantage of the event, engage with fellow attendees, and explore the many opportunities for collaboration and growth.

In 2024, CSTM hosted 3 virtual Education Days. Our February event was our heart themed, with focus on Cardiac issues. The July event focused on Maternal Fetal Medicine, and our October event was Halloween themed education on transfusion reactions. The goal for Education Days is to provide virtual content facilitating more educational opportunities for our members. The webinars are available for members on the CSTM website for viewing at any time. CSTM is also working with sponsors to develop educational content that will provide additional access to Transfusion Medicine resources.

We are so grateful to our sponsors who continue to support the CSTM Annual Conference and other CSTM activities such as our website, awards, and bursaries for the conference. The sponsorship funding is critical to the activities of our committees allowing them to produce resources such as the CSTM Standards and guidance statements, develop and undertake pediatric and obstetrical transfusion projects, and form networks of transfusion medicine specialists from across Canada who are available to answer questions from our membership and website visitors.

The CSTM Committees and Working Groups continue to meet and work throughout the year. The on-going CSTM committees are:

The Annual Conference Standing Committees and working groups

- The local Conference Organizing Committee
- The Canadian Obstetric and Pediatric Transfusion Network
- The Communications Committee
- The CSTM Standards Committee
- The Education Committee
- The Specialization in Transfusion Science Committee
- The Transfusion Safety Network

Please consider volunteering for one of our many committees and working groups. It is a wonderful way to develop your network across the country and give back to the transfusion medicine community. Complete a volunteer application at

https://www.transfusion.ca/Members/Board/Volunteers

CSTM engages its membership and public through multiple channels. The website reaches over 1,000 users per month, with just over sixty percent of the visitors viewing from Canada, and just under a quarter of the viewers joining from the United States. On social media, CSTM connects and shares updates, news, and resources on LinkedIn, X (formally Twitter), Instagram, Threads, Blue Sky and Facebook to a worldwide audience and shares recorded education sessions with its membership on YouTube. CSTM provides the engaging monthly newsletter 'CSTM Communique' to members and member-only resource section on its website, as well as access to the CSTM Standards. The CSTM Connect mailing list does not require a membership to join and it provides an opportunity for questions and answers from its current community of over 200 participants. Continue to look for the monthly updates and send all your Transfusion Medicine related questions to the CSTM Connect email list.

Whether you are here to learn, share, or connect, we hope that the CSTM Annual Scientific Conference will be a memorable and enriching experience. Our team is here to assist you in any way possible, so please don't hesitate to reach out if you have any questions or need support throughout the event.

We hope you enjoy the conference, as well as the charm of St. John's—the oldest city in North America. Be sure to take in the local attractions, including Signal Hill, Quidi Vidi Village, and the beautiful Iceberg Quest boat tours.

Thank you for being part of this exciting event. We look forward to a productive and inspiring conference experience together!

Joanna McCarthy

CSTM President



MESSAGE FROM CANADIAN BLOOD SERVICES



1800 Alta Vista Drive Ottawa ON K1G 4J5 blood.ca

Colleagues,

Welcome to the 2025 Canadian Society for Transfusion Medicine (CSTM) conference here in beautiful St. John's.

Once again, Canadian Blood Services is happy to have many from our transfusion community in attendance and to be sponsoring this important annual conference. This year's theme "no lab is an island" reminds us that it's events like these, that bring together our community of transfusion medical professionals, that truly make a difference. It's in this space that we learn from each other, build new connections, collaborate towards a new and exciting future, and to discover new things all in the name of improving the lives of patients in need.

It is in that spirit that I'd like to share with you what Canadian Blood Services has been working on, together with our partners, to improve patient care and safety. We are working together with the Blood Transfusion Genomics Consortium on a cutting-edge microarray genotyping platform — paving the way for precision-level matching of blood components. Work was completed over the last year to evaluate pathogen inactivation of apheresis plasma. Pending approval from our regulators, we hope to make this product available to hospitals in the fall. We are supporting a Canadian Institutes of Health Research-funded randomized trial on sex-matched versus sex-mismatched red cell transfusions — work that could transform future practice.

We have opened an innovation and discovery laboratory to perform surveillance studies and evaluate new testing approaches to transfusion transmissible pathogens. We are also assessing a newly licensed nucleic acid test for malaria and hope to integrate this test into our malaria risk mitigation strategy for donors, increasing eligibility while maintaining safety.

You may have noticed that I referenced "we" a lot in this letter. That was no accident. It is through working together as a whole that we drive towards a better future. These initiatives reflect the unwavering commitment of all of us to research that drives innovation, enhances safety, and improves lives.

My hope is that, in whatever capacity you are attending this conference, you return home with a renewed sense of fellowship. Because each and every one of you is an important part of building the shared future of transfusion medicine.

Sincerely,

Dr. Graham Sher, O.C

CEO

Canadian Blood Services

MESSAGE FROM HÉMA-QUÉBEC



Remarks from Héma-Québec's President and Chief Executive Officer

Héma-Québec is thrilled to be here for this year's Canadian Society for Transfusion Medicine Conference. This annual conference is such a wonderful opportunity for us to come together and, this year, we're lucky to be in beautiful St. John's to talk about the exciting challenges shaping the future of transfusion medicine.

This year's theme, *No Lab is an Island*, perfectly encapsulates the importance of working together in transfusion medicine. The challenges we face can only be overcome by sharing knowledge, offering support, listening and remaining open to new perspectives. It's no accident that cooperation is the central tenet of not just this conference, but the very mission of the Canadian Society for Transfusion Medicine.

The CSTM builds bridges between members of the scientific and medical community, forging links that encourage excellence and mutual support across the transfusion medicine community. Its vast partner network produces knowledge, improves practices, develops new technologies and builds capacity through trainings and collaboration. Now that's a winning formula!

Here's to making the most of the conversations, encounters and discoveries ahead of us. I hope you walk away inspired and motivated. Have a great conference!



Nathalie Fagnan, FCPA, ICD.D

President and CEO Héma-Québec

REGISTRATION INFORMATION

For any questions or further information during the event, there will be volunteers wearing a blue Newfoundland lanyard.



Registration Desk

To pick up your name badge and complementary material, visit the Registration Desk, located at St. John's Convention Centre lobby.


Speaker Ready Room

The Speaker Ready Room is located in the **Battery Room**. Speakers and moderators are encouraged to visit the Speaker Ready Room at least 15 minutes before the start time of their session.


Hours of Service – Registration Desk and Speaker Ready Room

Thursday May 29	0700-1600
Friday May 30	0700-1600
Saturday May 31	0700-1600
Sunday June 1	0700-1200

SJCC FLOOR PLAN LEVEL 2



SJCC FLOOR PLAN LEVEL 3



CONFERENCE AT A GLANCE

THURSDAY MAY 29 WORKSHOPS

0700-1600	REGISTRATION	Coat Check – Level 2
0800-1700	SPEAKER READY ROOM	Battery Room – Level 3
0730-0830	BREAKFAST	Lobby
0830-1000	Nightmares in Transfusion Medicine Workshop	Bannerman 2&4
1000-1030	BREAK	Lobby
1030-1200	Transfusion Reactions: Immune Reactions Workshop	Bannerman 2&4
1030-1200	New Products: What to do when you are expecting	Bannerman 1&3
1200-1330	LUNCH	Lobby
1330-1500	Complex Serological Case Studies Workshop	Bannerman 1&3
1330-1300	Standards Workshop: Inspections	Bannerman 2&4
1500-1530	BREAK	Lobby
1530-1700	Genomics Workshop	Bannerman 2&4
1830-2030	PRESIDENT'S RECEPTION	The Rooms – 9 Bonaventure Avenue

FRIDAY MAY 30 SCIENTIFIC PROGRAM

0630	Fun Run/Walk	Meet in the lobby of Delta
0700-1000	REGISTRATION DESK	Coat Check – Level 2
0800-1700	SPEAKER READY ROOM	Battery Room – Level 3
0730-0830	BREAKFAST	Lobby
0845-1000	Opening Remarks Keynote Address - "Your Wellness: The Truth About Self-care"	Bannerman 1234
1000-1030	BREAK	Bowring 1235
1030-1200	Sickle Cell Treatment Options	Bannerman 1234
	Blood Product Inventory and Distribution Logistics	Bowring 4
1200-1330	LUNCH	Bowring 1235
1330-1500	Treating Immune Platelet Disorders	Bannerman 1234
1550-1500	Donor Topics	Bowring 4
1500-1530	BREAK	Bowring 1235
1530-1700	Oral Abstracts #1	Bannerman 1234
1550-1700	Oral Abstracts #2	Bowring 4
1700-1800	POSTER VIEWING WITH AUTHORS	Bowring 1235
1730-1930	EXHIBITORS RECEPTION	Bowring 1235

SATURDAY MAY 31 SCIENTIFIC PROGRAM

0700-1000	REGISTRATION DESK	Coat Check – Level 2
0800-1700	SPEAKER READY ROOM	Battery Room – Level 3
0730-0830	BREAKFAST	Lobby
0730-0830	CSTM AGM/Breakfast Presentation of Awards and Bursaries	Bannerman 1234
0830-1000	QuidelOrtho Award Lecture CSTM Buchanan Award Lecture CBS Dana Devine Award Lecture Eliana Saidenberg TM Traineeship Award Presentations	Bannerman 1234
1000-1030	BREAK	Bowring 1235
	CBS & HQ Research Updates	Bowring 4
1030-1200	Compliance with Krever recommendations, practice standards and operational logistics in the era of out of hospital blood product infusion therapy in British Columbia	Bannerman 1234
1200-1330	LUNCH	Bowring 1235
1330-1500	COPTN, NAC, CCNMT Updates Session	Bowring 4
1990-1900	AI Applications in the Transfusion Medicine World	Bannerman 1234
1500-1530	BREAK	Bowring 1235
1530-1700	Bleeding Disorders	Bannerman 1234
1700-1830	CORPORATE NIGHT	


SUNDAY JUNE 1 SCIENTIFIC PROGRAM

0700-1000	REGISTRATION DESK	Coat Check - Level 2
0800-1200	SPEAKER READY ROOM	Battery Room - Level 3
0730-0815	BREAKFAST	Lobby
0815-0945	New Platelet & Plasma Products	Bannerman 1234
	Hemovigilance in Canada	Bowring 4
0945-1015	BREAK	Lobby
1015-1145	Diverse roles of non-MD staff supporting Transfusion Medicine – Panel Discussion	Bannerman 1234
1145-1200	CLOSING COMMENTS	Bannerman 1234

WATERFORD RIVER T'RAILWAY 5 KM FUN RUN/WALK MAP

Meet in Delta lobby at 6:30 AM





KEYNOTE SPEAKER

Gillian Whelan

Gill Whelan is the visionary founder and owner of Whelan Wellness Inc., and the creator of the innovative Whelan Wellness Virtual Bootcamp program. With a holistic approach to wellness, Gill works with clients around the globe, empowering them to enhance their well-being and evolve into their best selves while leading purposeful, fulfilling lives. Driven by a mission to transform our perceptions of wellness, Gill helps individuals rebuild their relationships with food and fitness, encouraging them to embrace self-love and acceptance. Her personal journey of



overcoming restrictive dieting and body image challenges inspired her to develop a unique 4-pillar system that has positively impacted thousands of lives worldwide. Recognized as a trailblazer in coaching, leadership, motivational speaking, and holistic wellness, Gill has been featured by notable media outlets including VOCM, CBC, Rogers TV, CTV News, NTV News, Atlantic Business Magazine, Best Health Magazine, and All Newfoundland and Labrador. Under her leadership, Whelan Wellness has earned prestigious accolades, including top platinum-level awards in St. John's Community Votes for Nutrition & Weight Loss, Fitness Centres & Gyms, and Personal Trainer for four consecutive years (2021-2024). In 2021, Gill was honored as Entrepreneur of the Year by NLOWE in the Momentum category, and in 2023, Whelan Wellness received the Opportunity Seeker award from the St. John's Board of Trade. Connect with Gill to embark on your journey toward holistic wellness and self-discovery.

CSTM AWARDS

CSTM BLUM AWARD

Crystal Brunk

Crystal Brunk has been a member of the Canadian transfusion medicine community since 2018, in that time she has sought to improve transfusion education accessibility and has advocated for the advancement of the nursing perspective and role in the field.

Crystal's commitment to education is evident through her involvement in multiple provincial education days, national conferences, and projects like the Canadian Blood Service's Learn Transfusion series, Genomics Transfusion Rounds, and CSTM's virtual education days. Her efforts in these areas have significantly



contributed to the dissemination of transfusion knowledge to those unable to attend in-person events like conferences.

Crystal holds a Graduate Certificate in Transfusion Practice from the University of Melbourne (2019), a Critical Care Nursing Specialty from British Columbia Institute of Technology (2012), and a Bachelor of Science in Nursing from McMaster University (2007). She is an active CSTM member as current co-chair for the Education Subcommittee, administrative support for the Canadian Obstetric and Pediatric Transfusion Network, active Transfusion Safety Network member, and annual conference abstract reviewer. She previously served as Director-at-large, was a founding co-chair of the Transfusion Safety Network and has sat on the conference scientific committee.

QUIDELORTHO AWARD

Dr. William Sheffield

Dr. William (Bill) Sheffield completed his doctoral degree in Biochemistry at McGill University in Montreal, Quebec in 1989. Dr. Sheffield joined the Faculty of Health Sciences at McMaster University in Hamilton, Ontario in 1992, where he is currently a full Professor in the Department of Pathology and Molecular Medicine. His research centres on plasma and plasma proteins. Dr. Sheffield has been part of the scientific staff of Canadian Blood Services and its predecessor for over thirty years, and is currently Associate Director, Research, with the organization.



CSTM BUCHANAN AWARD

Stacey Greeley

Stacey Greeley graduated from College of the North Atlantic in 2011 as a Medical Laboratory Technologist. Since then, she has been working at the Health Science Center in St John's, NL spending a short time in the Chemistry Lab and then devoting the last 13 years to the Hematology and Transfusion Medicine Department.

While rotating through these disciplines, Stacey also showed interest in the Stem Cell processing lab where she assisted with the autologous stem cell transplants alongside the hospital's clinical team from 2019 to 2021.

Stacey has been a senior technologist in the Transfusion Medicine Lab since 2022 where she works as a Technical Specialist.



She is a member of the Regional Transfusion Committee and performs on-call duties for the entire province of Newfoundland and Labrador.

When she is not working, Stacey enjoys spending time with her 7 year old son, husband and 100lbs Goldendoodle.

CANADIAN BLOOD SERVICES DANA DEVINE AWARD

Dr. Yoelys Cruz-Leal

Dr. Cruz-Leal got her Ph.D. with a "summa cum laude" degree in Biological Science, Biochemistry, and Molecular Biology and Immunology, University of Havana, Cuba, in 2014. During her doctoral studies, she focused on understanding the role of B-1 cells in the adjuvant properties of liposomes. In 2015, she joined the Faculty of Biology at the University of Havana as a Senior Research Associate. During this time, her work centered on the development of a novel adjuvant based on pore-forming proteins encapsulated in liposomes to induce robust antigen-specific cytotoxic T-cell



responses. Her contributions have advanced the understanding of liposome-based vaccine adjuvants and their potential to enhance vaccine efficacy.

Later, she joined Prof. Alan H. Lazarus's lab at the Canadian Blood Services as a postdoctoral fellow in April 2016. Her research has been focused on replacing anti-D immunoglobulin with a recombinant strategy, such as monoclonal antibodies, to prevent hemolytic disease in the fetus and newborn (HDFN). She has specifically studied the mechanism of trogocytosis related to the loss of red blood cell antigens and the impact of alterations in the IgG Fc region on immunosuppression. Her cover article in Blood, highlighting trogocytosis as a novel mechanisms underlying AMIS. She has also collaborated with leading transfusion medicine groups, including the Quality Utilization Efficacy Safety Transfusion (QUEST) group and The Canadian Transfusion Trials Group (CTTG), facilitating the translation of her basic research into clinical scenario.

Dr. Cruz-Leal has published <u>24 peer-reviewed articles</u> in leading journals in her field. Throughout her promising scientific career, she has received significant recognitions, including two Annual Biomedical Science Awards from the Cuban Academy of Sciences and an Award from the Young Scientists Program (YSP) of the International Union of Biochemistry and Molecular Biology (IUBMB) in 2014. Since 2018, she has been an active member of the Canadian Society of Transfusion Medicine and the Association for the Advancement of Blood and Biotherapies (AABB).

BURSARIES

2025 GRIFOLS LABORATORY TECH	NOLOGIST BU	URSARY IN	HONOUR	OF F	PAT
LETENDRE					

Sarah Buchko

Sarah McMahon

2025 CSL BEHRING NURSING BURSARY

Liana Perruzza

Melissa Greene

2025 CSTM SPEAKER LEGACY BURSARY

Rebecca Randall

Sebastian Vuong

POSTERS

Poster #	Poster Title	Presenting Author
1	Red blood cells from donors with diabetes are not differentially impacted by manufacturing stresses	Celina Phan
2	Investigating the Thaw-Time and Post Thaw Storage of Solvent Detergent (S/D) treated Plasma	Jeff Kinnery
3	Scoping review of social, ethical, and legal considerations of genomic sequencing	Kelly Holloway
4	Physician Management of Ig in Canada: A Qualitative Study	Kelly Holloway
5	A qualitative study of donors' views on uses of genomic sequencing in a blood donation context	Jennie Haw
6	Sera from Patients with Immune Platelet-Transfusion Refractoriness Primarily Drive FcyRIII-Dependent Platelet Destruction In Vitro and Clearance In Vivo in a Humanized Mouse Model	Lazaro Gil Gonzalez
7	Differential Roles for the Coagulation Factor X Gla-Domain During Activation	Lihua Hao
8	Impact of Cannabis Use on Platelet Quality: Implications for Blood Donors	Lionel Loubaki
9	Comparative oxygen delivery potency of young and old red blood cells	Mahsa Yazdanbakhsh
10	New cryopreservation model provides new insights into the sensitivity of hematopoietic stem cell and progenitors to cryostorage	Nicolas Pineault
11	Temporal trending of seasonal Influenza and HIV-1&2 serological false positive results in blood donor testing	Nicole Vansenus
12	The ability of Cutibacterium acnes to establish chronic infections is heightened in the platelet storage environment	Sandra Ramirez- Arcos
13	Biofilm Formation by Acinetobacter baumannii Strains involved in Septic Transfusion Reactions is Stronger in Platelet Concentrates Prepared in 100% Plasma Compared to Platelet Additive Solution	Yuntong Kou
14	How to create evidence to re-evaluate universal syphilis testing for blood donors?	Sandra Ramirez- Arcos
15	Innovative Antifouling Bead-Based Platform for Identification of Novel Platelet Receptor Ligands	Sladjana Slavkovic

	RBC quality when a prototype DEHP-free collection set is used with Canadian Blood Services whole blood-derived component production	Tatiana
16	processes	Stephenson
	Evidence for Trogocytosis in RhIG-Mediated Immune Suppression: A	
17	Paradigm Shift in HDFN Prevention	Yoelys Cruz Leal
18	Cryopreservation of red blood cells with isochoric freezing	Yuanheng Zhao
19	Changes in Intravenous or Subcutaneous Immunoglobulin Usage Before and After Efgartigimod Initiation in Patients With Myasthenia Gravis	Alexis Fuhr
20	Sustainability and cost-avoidance of reduced inappropriate red cell transfusion at community hospitals: A follow-up analysis on a Quality Improvement initiative.	Alexis Fang
21	Unusual spike in PTP cases in Canada - Not so rare anymore?	Ann Peregrin
22	Impact of doctor's care on eligibility in Canadian blood donors	Anna Hu
23	Evaluation of the Seasonal Timing for Universal West Nile Virus Testing in Canadian Blood Donors: Is an Earlier Start Needed?	Carmen Charlton
24	High-Sensitivity Detection of Low-Level Malaria Parasitemia for Blood Donor Screening	Carmen Charlton
25	Oh Baby: A Review of Pregnancy Outcomes in Women with Bombay Phenotype	Catherine Lovatt
26	A unique example of a Cromer system antibody	Chris Kong
27	Asymptomatic West Nile Virus Positivity Amongst Canadian Blood Donors Compared to Clinically Reported Cases	Cynthia Cranney
28	Is there value in sharing donor information with other blood agencies?	Elaine Fournier
29	Utilization Performance Indicators: Improving Component Utilization Through Data Analysis and Visualizations.	Jennifer LeFrense
30	Exploring Physician-related Transfusion Errors reported to the Transfusion Error Surveillance System (TESS) from 2016-2023: A single centre study	Julia Lou
31	Transfusion practices and management for multi-transfused patients with Anti-Jsb alloimmunization.	Karen Kong
32	Analysis of Stem Cell Club Donor Recruitment Outcomes: Ten Years in Review	Margarita Conway
33	Antenatal immunohematology: a review of two large provincial testing programs	Lhevinne Ciurcovich


	<u> </u>	1
34	Empowering the Transfusion Medicine Community: The Impact of National Education	Crystal Brunk
35	A comparison of manual and automated gel technology vs manual saline indirect antiglobulin test in prenatal antibody titration	Melanie Bernabe
36	The impact of pathogen reduced platelet implementation on manufacturing and process metrics	Michelle Zeller
37	Impact of pathogen reduced platelet implementation on adverse transfusion reaction reporting	Michelle Zeller
38	Education and knowledge translation initiatives supporting pathogen reduced platelet implementation by a Canadian blood and biologic supplier	Michelle Zeller
39	Education and knowledge translation initiatives supporting solvent detergent plasma implementation by a national blood supplier	Kathryn Webert
40	Non-Invasive Prenatal Testing in Canada: Side-by-Side Evaluation of Two Platforms for Fetal RHD Screening	Narisha Shakuralli
41	Small volume platelet orders: Can aliquot validation improve platelet conservation?	Susan Nahirniak
42	Transfusion Service Transformation	Bryan Tordon
43	Bridging the Gap: Navigating document management after the loss of an eDMS	Jessica Okerman
44	Impact on solvent detergent plasma implementation on adverse transfusion reaction reporting	Nour Alhomsi
45	Emergency red blood cell utilization in Saskatchewan hold-blood sites: a 5-year audit	Oksana Prokopchuk-Gauk
46	Comparison of Frozen Plasma and Solvent-Detergent Plasma Thaw Times: A Single-Centre Validation Study	Oksana Prokopchuk-Gauk
47	Risk of high volume antenatal feto-maternal hemorrhage (FMH) in Rh negative pregnancies. What is the role of antenatal testing for FMH?	Sarah Tehseen
48	Turning the Tide: Transforming O RhD Negative RBC Management	Sarah McMahon
49	Platelet Intrauterine Fetal Transfusion	Shelley Anne Solomon
50	Anti-KEL1 titration in pregnancy: a method comparison study	Tammy Bartok
51	Creation of the Canadian Blood Group Genomic Reference Database: a Curated Tool to Support Precision Transfusion Medicine.	Teenus Paramel Jayaprakash

	T	T
52	Manual Method versus ECHO Lumena DAT-C3d Test Validation	Wendy Kavanagh
53	Cost-effectiveness of reaching Ig self-sufficency targets using alternative treatments to reduce demand compared to increasing supply	Julien McDonald- Guimond
54	Automation and Workload Assessment in the Transfusion Medicine Laboratory	Susan Nahirniak
55	Reducing Unnecessary Type & Screen Testing in Planned C-Sections: A Provincial QI Approach	Susan Nahirniak
56	The National HLA/HPA Selected Platelet Program: Utilization trends in Canada	Natasha Rickards
57	Development and feasibility of a national prehospital transfusion registry: insights from the Blood on Board program at Ornge	Noah Zweig
58	Analysis of the 2024 IQMH patterns of practice survey on provision of transfusion services and blood products to affiliated laboratories, subsidiary facilities, and other programs.	Chang-Keun Lee
59	Exploration of Participant Responses to the 2024 IQMH Educational Survey and Discrepancies in Practice Across the Province.	Chang-Keun Lee
60	Cord DAT strength correlates with the need for neonatal phototherapy	Nora MacNeil
61	Comparative evaluation of automated column agglutination technique versus manual conventional tube isohemagglutinin titration in ABO-incompatible renal transplant	Jian Jing
62	Designing Canada's Blood Supply Chain for the 2030's	John Blake
63	Post-Pandemic Trends and Regional Variability in Red Blood Cell Issuance Across Canada	John Wall
64	Development of Knowledge Translation Toolkit for the Canadian Transfusion Trials Group	Kathryn Corbett
65	E-learning for Transfusion Consent: Developing a Novel Educational Tool	Marissa Laureano
66	Calculating Capacity: A Workload Model for Transfusion Medicine Physicians in Ontario	Marissa Laureano
67	Massive hemorrhage protocol activation in a tertiary hospital network: a 3-year retrospective quality improvement audit using quality indicators	Phillipe Price
68	Implementing Best Practice Guidelines for Sickle Cell Disease at a Community Teaching Hospital	Thodora Ruijs
69	Updating a provincial MHP through a modified Delphi: What has changed?	Stephanie Cope

70	Evolution of a Massive Hemorrhage Protocol Quality Metrics Portal	Alison Wendt
71	Compliance in Blood Administration: Insights from the 2023 Provincial Bedside Audit	Tracy Cameron

EXHIBITORS LIST AND BOOTH LIST

Exhibitors	
Grifols	CSL Behring
Intermedico	Vertex
Fresenius Kabi Canada Ltd.	Alberta Precision Laboratories
Best Theratronics	Haemonetics
Bio-Rad	ORTHO
Argenx Canada	Pfizer Canada
Recordati Rare Diseases Canada Inc.	Hema-Quebec
CSTM 2026	WellSky
Takeda	Werfen
CBS	Octapharma
Cerus	



THANK YOU TO OUR EXHIBITORS



Biotherapies for Life® CSL Behring





















BLOOD and PLASMA MOTHER'S MILK STEM CELLS HUMAN TISSUES





















THANK YOU TO OUR SPONSORS AND PARTNERS

PLATINUM SPONSORS





GRIFOLS



SILVER SPONSORS





BRONZE SPONSORS





PARTNERS





DETAILED SCIENTIFIC PROGRAM

Welcome to the Canadian Society for Transfusion Medicine's 2025 Annual Conference – No Lab is an Island. This conference is designed for all professionals working in or interested in transfusion medicine, including physicians, fellows, medical residents, laboratory technologists, nurses, transfusion safety officers, and scientists.

Conference general objectives

By the end of this conference, attendees should be able to

- 1. Manage important changes and new strategies in the setting of transfusion medicine.
- 2. Describe current and emerging Canadian transfusion research.
- 3. Identify best practices in laboratory and clinical quality systems.
- 4. Establish and foster inter-collaborative relationships with colleagues.

Thursday Ma	ay 2 9		
0700-1600	Registration	Coat Check – Level 2	
0800-1700	Speaker Ready Room	Battery Room – Level 3	
0730-0830	Breakfast	Lobby	
0830 - 1000	Assailant in the Lab - What Would \ Nicole Gettle	You Do?	Bannerman 2&4
Nightmares in	Objectives:		
Transfusion	1. Inspire thought about how you w	ould handle a terrifying	
Medicine	situation		
Workshop	2. Share how this situation was hand other site processes3. Enhance Awareness of Security P		
Moderator: Akash Gupta	Blood Transfusion Lab Nightmare: I Managing) a Sudden Surge in Dema Globulin in a Local Hospital Networ Farzana Tasmin Objectives: 1. Analyze the operational and clinic during a sudden surge in product denetwork. 2. Describe the effective interprofess staff, TSO and physicians can stay contimely patient care. 3. Reflect on lessons learned to stree preparedness in transfusion services	and for a Hyperimmune ck cal challenges and key decisions emand within a hospital ssional strategies on how the lab pordinated to ensure safe and ingthen future surge	
	The Puzzle of Panreactivity Sarah Buchko Objectives: 1. Provide a differential diagnosis fo 2. Recognize challenges with obtain	•	

	Provincial Hypofibrinogen Jian Mi	
	Objectives:	
	 Communication among clinical, TM lab, and CBS Educate staff of multiple brands of products available 	
1000-1030	Break	Lobby
1030 - 1200 Transfusion	Immune Reactions: Definitions & Classifications Matthew Yan Objectives: 1. Compare and contrast the immunobiology between different types of immune-related transfusion reactions. 2. Describe an approach to assess and classify immune-related	Bannerman 2&4
Reactions Immune	transfusion reactions.	
Reactions Workshop	Case presentation- A patient with sickle cell anemia Jordan Radigan Objectives:	
Moderator: Rebecca Rock	 Discuss guidelines for pre-operative transfusion in patients with sickle cell disease Discuss pre-transfusion testing strategies in patients with sickle 	
	cell disease 3. Review immune related transfusions in patients with sickle cell disease	
	Transfusion Reactions - Immune Reactions Ali Tabatabaey Objectives:	
	 Identify clues to immune reactions in the context of transfusion Categorize differential diagnoses for platelet refractoriness Describe and interpret advance testing in the setting of platelet refractoriness after transfusion. Formulate a management plan for a rare immune transfusion reaction 	
1030 - 1200 New Products:	What To Expect When ExpectingFrom Conception to Delivery An end-to-end review of implementation of new TM Inventory Bruce Lyon, Jessica Okerman, Marie-Hélène Robert	Bannerman 1&3
What to do when	Objectives:	
you are expecting	 By the end of this session, participants will be able to explain the different steps implemented by Héma-Québec leading to the introduction of a new blood component or product to partner hospitals. By the end of the presentation, participants will be able to identify the steps required to make a new component or product 	
Moderator: Eileen McBride	available within a hospital, from a quality and document management viewpoint 3. By the end of the presentation, participants will be able to identify the steps required to make a new component or product available within a hospital, from a research and development perspective.	
1200-1330	Lunch	Lobby

4000 4777	[a]	
1330-1500	Choose your adventure! Exploration with investigations - complex	Bannerman 1&3
	serological case studies	
	Johnny Mack, Chris Kong	
	Objectives:	
	1. Enhance accuracy in the interpretation of immunohematologic	
Complex	test results.	
Serological Case	2. Strengthen critical thinking and analytical skills to facilitate	
Studies Workshop	advanced antibody identification and investigation.	
	3. Apply technical expertise to efficiently and effectively resolve	
	serologic challenges.	
Moderator: Jenn	Which comes first C. B. or C	
Danielson	Which comes first C, D or G.	
	Jacqueline Cote Objectives:	
	Strengthen critical thinking and analytical skills for antibody	
	identification.	
	Apply theoretical and practical knowledge to efficiently resolve	
	unknown antibody/ies specificity and the determine the clinical	
	implication of the antibody/ies.	
	implication of the untibody/ies.	
1330-1500	Want to Being an Assessor? It's harder than you think!	Bannerman 2&4
322 223	Danielle Watson	
	Objectives:	
Standards	Understand how inspector's prepare for an inspection	
Workshop -	Understand training and on-going competency for inspector's	
Inspections	3. Understand the types of citations and expectations of citation	
	responses	
Moderator:		
Susanna Darnel	Citation Response	
	Clare O'Reilly	
	Objectives:	
	1. Understand how to develop an organized response to a citation	
	2. Understand the difference between initial and final responses	
	3. Understand how to engage the appropriate staff to address a	
	citation	
	A Citation A Bushless Cabine Issuers	
	A Citation, A Problem-Solving Journey! Kristin Rosinski	
	Objectives: 1. Define strategies and resources to address citations	
	Apply strategies and resources to example citations	
	2. Apply Strategies and resources to example citations	
1500-1530	Break	Lobby - Second Floor
1530-1700	When Two Worlds Collide	Bannerman 2&4
	Nadia Baillargeon, Karine Plourde, Akash Gupta, Teenus Paramel	
Genomics	Jayaprakash	
Workshop	Objectives:	
-	Review analysis of simulated clinical cases where molecular	
	testing was used to aid difficult serology	
Moderator: Kristin	2. Discuss current methods for red cell and platelet genotyping in	
Rosinski	addition to serological methods	
	3. Review an approach to phenotype/genotype descrepancies	
1830-2030		The Rooms – 9
	PRESIDENT'S RECEPTION	Bonaventure Avenue

Friday May	30		
0630	Fun Run	Meet in the Delta Hotel Lobby	
0700 -1600	Registration	Coat Check – Level 2	
0800-1000	Speaker Ready Room	Battery Room – Level 3	
0730-0830	Breakfast	Lobby	
0845-1000	Opening Remarks		Bannerman 1234
Plenary Session	Joanna McCarthy		
	Melissa Dawe & Akash Gupta		
	Keynote Address - "Your Wellne Gill Whelan	ess: The Truth About Self-care"	
1000-1030		Break	Bowring 1235
1030 - 1200	of Canadian Patients. Nicole Prokopishyn Objectives:	of Care Manufacturing for Treatment cell and gene therapies being utilized	Bannerman 1234
Sickle Cell	in Canada to treat patients.	cell and gene therapies being utilized	
Treatment	•	tories in Canada in advancing the	
Options	access of novel therapies.		
Moderator: Kristin Rosinski	of Sickle Cell Disease Ziad Solh Objectives: 1. To review pharmaceutical the 2. To review transfusion indicati	ions for SCD	
	Role of the Blood Supplier Matthew Yan Objectives: 1. Review current approaches at cell orders for people with sickle 2. Describe continuous quality in potential future state in providin with sickle cell disease.	mprovement initiatives and the ng transfusion support for people	
1030 - 1200	The Logistics of Rural and Remo David McKee Objectives:	ote Blood Collection and Delivery	Bowring 4

Blood Product	1. Participants will obtain an understanding of the challenges faced	
Inventory and	in collecting blood and the delivery of blood and blood products in	
Distribution	rural and remote locations.	
Logistics	2. Participants will develop an understanding of the solutions	
208.00.00	currently employed by Canadian Blood Services and emerging	
	technologies that may be on the horizon.	
Moderator:	teermologies that may be on the nonzon.	
Rebecca Rock	Pland Product Inventory and Distribution Logistics	
REDECLU NOCK	Blood Product Inventory and Distribution Logistics	
	Jennifer Ciccarelli-Guevara	
	Objectives:	
	1. Understand Héma-Québec's blood product distribution and	
	transport services offered to remote areas across Quebec. Specific	
	case studies will be presented as supporting material.	
	2. Understand Héma-Québec's current transport plan and future	
	developments with selected hospitals.	
	3. Know the action plans put in place by Héma-Québec to adequately	
	supply inventory to these remote areas.	
	Blood Product Inventory and Distribution Logistics	
	Jacob Pendergrast	
	Objectives:	
	To discuss the challenges of blood product inventory management	
	in rural and remote areas	
	2. To explore options to enhance delivery and maximize local	
	resources	
1200-1330	Lunch	Bowring 1235
1200 1330	Luncii	Downing 1233
1220 1500	Autoimmuno and Allaimmuno Distalet Disaudore	Dannarman 1224
1330-1500	Autoimmune and Alloimmune Platelet Disorders	Bannerman 1234
1330-1500	Donald Arnold	Bannerman 1234
	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis	Bannerman 1234
Treating Immune	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management	Bannerman 1234
Treating Immune Platelet	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment	Bannerman 1234
Treating Immune	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management	Bannerman 1234
Treating Immune Platelet	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches	Bannerman 1234
Treating Immune Platelet	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics	Bannerman 1234
Treating Immune Platelet	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch	Bannerman 1234
Treating Immune Platelet Disorders	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives:	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used.	Bannerman 1234
Treating Immune Platelet Disorders	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used.	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives:	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives: 1. Describe the rationale and process used to develop the National	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives: 1. Describe the rationale and process used to develop the National Plan for Management of Shortages of Immunoglobulin (Ig) Products	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives: 1. Describe the rationale and process used to develop the National Plan for Management of Shortages of Immunoglobulin (Ig) Products 2. Summarize existing challenges with accessing therapeutic options	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives: 1. Describe the rationale and process used to develop the National Plan for Management of Shortages of Immunoglobulin (Ig) Products 2. Summarize existing challenges with accessing therapeutic options as alternatives to Ig for clinical conditions	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives: 1. Describe the rationale and process used to develop the National Plan for Management of Shortages of Immunoglobulin (Ig) Products 2. Summarize existing challenges with accessing therapeutic options as alternatives to Ig for clinical conditions 3. Reflecting on the outcomes of a recent national Ig shortage	Bannerman 1234
Treating Immune Platelet Disorders Moderator:	Donald Arnold 1. Immune Thrombocytopenia (ITP): New approaches to diagnosis and management 2. Fetal and Neonatal Alloimmune Thrombocytopenia: Treatment approaches The Future of IVIG Mimetics Don Branch Objectives: 1. Learn for what conditions IVIG is used. 2. Be aware of the different IVIG mimetics that are composed of immunoglobulin fragments or blocking antibodies to various Fc receptors 3. Learn the state of the art for small molecule development to replace IVIG Development of a National Plan for Managing an Immunoglobulin Product Shortage Oksana Prokopchuk-Gauk, Cheryl Doncaster Objectives: 1. Describe the rationale and process used to develop the National Plan for Management of Shortages of Immunoglobulin (Ig) Products 2. Summarize existing challenges with accessing therapeutic options as alternatives to Ig for clinical conditions	Bannerman 1234

1330-1500	From ferritin to hemoglobin - Donors survey results about iron stores and mitigation measures	Bowring 4
	Jessyka Deschenes	
Donor Topics	Objectives: 1. Understand the impact of frequent whole blood donations on the hemoglobin level, iron stores and behaviour of Héma-Québec whole blood donors.	
Moderator: Sasha Hayse	Variant Creutzfeldt-Jakob disease and transfusion: assessing and managing a 'submerging' risk Marc Germain	
	Objectives: 1. Briefly present the history of donor travel deferrals for mitigating the risk of transmitting variant Creutzfeldt-Jakob (vCJD) disease through transfusion	
	vCJD: a tale of an emerging and submerging pathogen Anna Hu Objectives:	
	1. After this session, participants will understand the evolution of vCJD donor policy over time as the epidemiology of the disease changed.	
1500-1530	Break	Bowring 1235
1530-1700	The Association Between Anemia and Bleeding in Thrombocytopenic Patients with a Hematological Malignancy Dimpy Modi	Bannerman 1234
Oral Abstracts #1	Clash of the Standards: An Institutional Approach to Fulfilling ABO Confirmation Mandates While Upholding Patient Blood Management Principles Lisa Richards	
Moderator: Rebecca Barty	Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery - The FARES-II (LEX-211) Phase 3, Multicentre, Randomized, Clinical Trial Keyvan Karkouti	
	Rare Blood Program Review: Managing Transfusion Requirements During Pregnancy Nicole Relke	
	Blood consumption in patients with gunshot wounds: A Canadian single-centre experience Ali Tabatabaey	
	Intravenous Albumin Utilization and Guideline Compliance: A Multi-Center Audit of 607,304 Admissions at 16 Hospitals Nicole Relke	
1530-1700 Oral Abstracts #2	Modulating recombinant clotting factor X to improve clot- dissolution Alexandra Witt	Bowring 4

Moderator: Eileen	Challenging the "Low-Effector" Paradigm: IgG4-Based Monoclonal	
McBride	Antibodies Can Mediate Erythrophagocytosis	
	Alequis Pavon Oro	
	Comparison of the in vitro quality of irradiated DEHP/SAGM and	
	DEHT/PAGGSM red cell concentrates	
	Carly Olafson	
	In Vivo Evidence Linking Loss of Red Blood Cell Deformability to	
	Circulatory Clearance	
	Emel Islamzada	
	Distinct IgG-sensitization levels drive macrophage preference for	
	RBC trogocytosis versus phagocytosis	
	Zoya Hussain	
	Donor Red Blood Cell Deformability as a Predictor of Circulatory	
	Persistence in Transfusion-Dependent Thalassemia Patients	
	Hongshen Ma	
1700-1800	POSTER VIEWING WITH AUTHORS	Bowring 1235
1730-1930	EXHIBITOR'S RECEPTION	Bowring 1235

Saturday May 31			
0700-1600	Registration	Coat Check – Level 2	
0800-1700	Speaker Ready Room	Battery Room – Level 3	
0730-0830	Breakfast	Lobby	
Moderator: CSTM Board	CSTM AGM/Breakfast Presentation of Awards and Bursal CSTM Blum Award Grifols Bursaries in honou CSL Behring Nursing Bursal CSTM Speaker Legacy Bur QuidelOrtho Award CSTM Buchanan Award CBS Dana Devine Award	r of Pat Letendre aries	Bannerman 1234
0830-1000 Plenary Session <i>Moderator:</i> <i>Rebecca Rock</i>	QuidelOrtho Award Lecture William Sheffield CSTM Buchanan Award Lecture Stacey Greeley CBS Dana Devine Award Lecture Evidence for Trogocytosis in RhIG-Mediated Immune Suppression: A Paradigm Shift in HDFN Prevention Yoelys Cruz Leal Eliana Saidenberg TM Traineeship Award Presentations		Bannerman 1234

1000-1030	Break	Bowring 1235
1030 - 1200	Platelet-immunity crosstalk: Implications in thrombocytopenia	
	and IVIG alternative therapies	Bowring 4
	Heyu Ni	
CBS & HQ	Objectives:	
Research Updates	1. TBD	
	Vascular injury derived extracellular vesicles and autoimmunity	
	Mélanie Dieudé	
	Objectives:	
Moderator: Akash	1. Participants will learn about the diversity of circulating	
Gupta	extracellular vesicles in blood.	
	2. Participants will appreciate the unique profile of vascular injury	
	derived vesicles	
	3. Participants will understand the impact of vascular injury	
	derived extracellular vesicles in autoimmune responses of	
	importance in different conditions.	
	Designer proteins based on the human plasma protein alpha-1	
	antitrypsin	
	William Sheffield	
	Objectives:	
	1. To describe the current use of antitrypsin concentrates in	
	transfusion medicine	
	2. To explain how test tube selection is used to make designer	
	proteins	
	3. To balance the strengths and weaknesses of the designer	
	protein approach to inhibiting coagulation factors	
	Production of granulocyte concentrates using the REVEOS®	
	automated system	
	Mélissa Girard	
	Objectives:	
	To describe the steps involved in producing granulocyte	
	concentrates from residual leukocyte bags using the REVEOS®	
	automated system and the LR EXT device.	
	2. To explain criteria for compliance with the Canadian Standard	
	(CSA-Z902-20) for granulocyte concentrates.	
	3. To discuss the importance of transfusing granulocyte	
	concentrates within 24 hours of pool formation, based on the	
	functional capabilities of neutrophils.	
1000 1000		
1030 – 1200	Compliance with Krever Recommendations in the era of out of	Bannerman 1234
Compliance	hospital blood product infusion therapy in British Columbia.	
Compliance with Krever	Doug Morrison, Susanna Darnel, Kristin Rosinski Objectives:	
recommendations,	1. To understand the relevance of the Krever recommendations	
practice standards	with respect to home infusion therapy.	
and operational	To review Canadian transfusion medicine standards that govern	
logistics in the era	relevant blood products.	
of out of hospital	To understand the difficulties presented by out-of-hospital	
blood product	infusion therapy relevant to the Krever recommendations and	
infusion therapy in	transfusion medicine standards.	
British Columbia		
1	L	1

Moderator: Nicole		
Gettle 1200-1330	Lunch	Bowring 1235
1330-1500 COPTN, NAC, CCNMT Updates	Not just the usual suspects: uncommon alloantibodies and their association with hemolytic disease of the fetus and newborn Catherine Lovatt Objectives: 1. Describe the rationale and approach for identification and monitoring of maternal red cell alloantibodies in pregnancy 2. Appraise the literature regarding pregnancy management and	Bowring 4
Session	neonatal outcomes for pregnant people with unusual alloantibodies Do Duffy and Kidd lead to hemolytic disease of the fetus and	
Moderator: Danielle Watson	newborn? Noah Zweig Objectives: 1. Summarize the association in the literature between anti-Duffy (Fya, Fyb) and anti-Kidd (Jka, Jkb) alloantibodies and hemolytic disease of the fetus and newborn 2. Identify gaps in the literature regarding the clinical significance of anti-Duffy (Fya, Fyb) and anti-Kidd (Jka, Jkb) alloantibodies in the context of hemolytic disease of the fetus and newborn	
	NAC Update Andrew Shih Objectives: 1. To review the mandate and workplan updates from NAC 2. To highlight new publications from NAC 3. To explore joint collaborations with other medical societies and key partners	
	2024-2025 CCNMT Update Vincent Laroche Objectives: 1. Describe competing issues relevant to reevaluation of CCNMT's role in making recommendations on drugs or biotherapies replacing blood products. 2. Review indications and use of autologous blood donation in Quebec and present CCNMT's recommendations on autologous blood donation. 3. Describe trends in growth in IVIg utilisation in Quebec and the impact of mitigation measures implemented in the past year.	
1330-1500 Al Applications in the Transfusion Medicine World Moderator:	Application of AI in TrAnsfusion Medicine Calvino Cheng Objectives: 1. After attending the session, the participants should be able to cite up-to-date AI-related studies in transfusion medicine 2. After attending the session, the participants should be able to understand strengths and limitations of AI in transfusion medicine	Bannerman 1234
Rebecca Barty	Al and Machine Learning in Transfusion Medicine: Enhancing Blood Supply Chain, Diagnostics, and Outcome Prediction	

	Na Li Objectives: 1. Describe how advanced machine learning techniques are applied to transfusion medicine. 2. Explain the potential challenges, ethical considerations, and future directions of Al applications in transfusion medicine to enhance clinical decision-making and operational efficiency. Lab-on-a-chip technologies and multiplex biosensors towards big data applications including transfusion sciences Karen Cheung Objectives: 1. At the end of this presentation, audience members should be able to state and describe the fundamental elements of a multiplex biosensor. 2. At the end of this presentation, audience members should be able to describe how a label-free biosensor can be used to detect analytes.	
1500-1530	Break	Bowring 1235
1530-1700 Plenary Session	Caring for People with Bleeding Disorders: A Rural and Remote Community Perspective	Bannerman 1234
Bleeding Disorders	Natasha Pardy, Coleen Moores, Leonard Duffenais Objectives: 1. Consider the relevance of geography in caring for patients with	
Moderator: Melissa Dawe	rare bleeding disorders 2. Discuss the importance of education, communication, and collaboration in treating patients with bleeding disorders in rural and remote areas	

Sunday, June 1			
0700-1000	Registration	Coat Check – Level 2	
0800-1200	Speaker Ready Room	Battery Room – Level 3	
0730-0815	Breakfast	Lobby	
0815-0945	Innovative Platelet Products: Advancements and Clinical Bannerman 1234		Bannerman 1234
	Applications		
	Marc Cloutier		
New Platelet &	Objectives:		
Plasma	1. By the end of this conference or session participants will be		
Products	equipped to evaluate the advantages and limitations of emerging		
	platelet products, including frozen platelets, cold-stored platelets,		
	and lyophilized platelets.		
	2. By the end of this conference or session participants will be able		
	to formulate strategies for the implementation of emerging platelet		
Moderator:	products in clinical practice, considering factors such as storage,		
Danielle Watson	Advances in lyophilized plasma and spray-dried plasma		
	William Sheffield		
	Objectives:		
	1. To explain the potential advantages	of dried plasma products for	
	patients and transfusion services		

	as clinical products 3. To understand the status of dried plasma projects at Canadian Blood Services	
	Strategic watch on new platelet and plasma products at Héma- Québec	
	Amaury Gaussen	
	Objectives:	
	1. By the end of this session participants will be able to perform a	
	landscape analysis 2. By the end of this session participants will be able to use a	
	methodology of strategic watch	
0815-0945	A Canadian Call to Action: Saving Hemovigilance	Bowring 4
	Andrew Shih Objectives:	
Hemovigilance	To expand on the development and role of hemovigilance in	
in Canada	Canada	
	2. To discuss the current challenges of the Blood Safety Contribution	
	Program sunsetting 3. To discuss potential next steps for hemovigilance in Canada	
	3. To discuss potential flext steps for flemovigilance in Canada	
Moderator:	Transfusion Medicine in Newfoundland and Labrador	
Kristin Rosinski	Carla Shea	
	 Geographical struggles in Newfoundland and Labrador Inter hospital Transfer of Blood Products 	
	2. Intel hospital transfer of blood Froducts	
	Updating Transfusion Reaction Definitions: Quebec's experience	
	Pierre Aurèle Morin	
	Objectives:1. Discuss the process of reviewing hemovigilance definitions in	
	Quebec	
	2. Highlight differences between current definitions in Quebec and	
	the rest of Canada	
	3. Reflect on the ruture steps to improve pan-canadian collaboration	
0945-1015	Break	Lobby
1015-1145	Diverse roles of non-MD staff supporting Transfusion Medicine -	
Diverse roles of		Bannerman 1234
non-MD staff		
supporting	Objectives:	
Transfusion	1. The attendee will be able to describe the diverse approaches and	
	· · · · · · · · · · · · · · · · · · ·	
Medicine –		i e e e e e e e e e e e e e e e e e e e
Medicine – Panel Discussion	2. The attendee will be able to describe Quebec TSO survey results, conclusions, and changes proposed	
Panel	conclusions, and changes proposed	
Panel Discussion Moderator:	•	
Panel Discussion	•	
Panel Discussion Moderator:	conclusions, and changes proposed	Bannerman 1234
Panel Discussion Moderator: Rebecca Rock	•	Bannerman 1234
1015-1145 Diverse roles of non-MD staff supporting	3. Reflect on the future steps to improve pan-Canadian collaboration Break Diverse roles of non-MD staff supporting Transfusion Medicine - Panel Discussion Heather Panchuk, Widad Abdulwahab, Bianca Brunet, Vincent Laroche, Carla Shea Objectives: 1. The attendee will be able to describe the diverse approaches and roles supporting Transfusion Medicine across the country	Lobby Bannerman 1234



Things to do in St. John's

Iceberg Quest - Join Newfoundland's award-winning boat tour Iceberg Quest, departing from the heart of downtown St. John's. Walking distance from hotels, this two hour fully narrated tour lets you experience Cape Spear, Cabot Tower and Fort Amherst from the sea. https://icebergquest.com/st-johns-boat-tours/

43

Johnson Geo Centre - Cut from the ancient rock of Signal Hill, we take you deep underground to experience the story of our earth and beyond. Explore the interactive exhibits on your own or join our interpreters on a guided tour. Newfoundland & Labrador's premier science center, the Geo Centre makes for a fantastic activity, rain or shine. https://mun.ca/geocentre/

The ROOMS - The Rooms is Newfoundland and Labrador's largest public cultural space and home to its most extensive collection of artifacts, art and archival records. We are proud



custodians of our province's colorful history and creative spirit. We draw upon our collections to bring our province's rich stories to life in engaging, multi-sensory, experiences. This unmistakable building is designed to reflect and celebrate our heritage. From our perch we offer unparalleled views of our harbor city. https://www.therooms.ca/

Signal Hill - Explore the iconic Cabot Tower and experience a view of St. John's and the North Atlantic that is truly spectacular. https://www.newfoundlandlabrador.com/trip-ideas/travel-stories/signal-hill-national-historic-site



Quidi Vidi Village - This quaint fishing village located just in the east end of St. John's will transport you to a different time. From the idyllic cottages dotting the roadside to the wharf lined with colorful fishing stages, Quidi Vidi, pronounced as Kitty Vitty or Quada Vida, depending on who you ask, offers a glimpse into the quintessential island outports of Newfoundland & Labrador. A can't miss for Quidi Vidi is the quaint Quidi Vidi Brewery https://destinationstjohns.com/a-day-in-quidi-vidi-nl/

Cape Spear - If you stand here, your back to the sea, the entire population of North America stretches out in front of you. And there's nothing behind you until Ireland. Perched on a rugged cliff, at our continent's most easterly point, sits Cape Spear Lighthouse — the oldest surviving lighthouse in the province, a National Historic Site, and an iconic symbol of Newfoundland and Labrador's marine history. https://www.newfoundlandlabrador.com/destinations/cape-spear

Shopping - From locally made artisan crafts to international fashion and specialty shops, downtown offers you a unique shopping experience you won't find anywhere else in the city.

https://destinationstjohns.com/plan-your-trip/shopping/


Eat and Drink - St. John's has a wide variety of culinary options – from pubs and cocktail lounges to fine dining, there is something for everyone. There are also great craft breweries to check out in the area as well. **https://destinationstjohns.com/plan-your-trip/food-drink/**

You cannot mention food and drink in downtown St. John's without calling attention to the world famous George Street.

George Street in downtown St. John's is two blocks of bars, pubs, restaurants – and nothing else. It's the center of the entertainment district and its unique reputation has spread far and wide. It has inspired songs and stories, and has been a magnet for musicians and their fans for decades.

https://www.newfoundlandlabrador.com/trip-ideas/travel-stories/george-street

East Coast Trail: The East Coast Trail has 25 paths to explore. These paths take you past towering cliffs and headlands, sea stacks, deep fjords, and a natural wave-driven geyser called the Spout. Experience abandoned settlements, lighthouses, ecological reserves, seabird colonies, whales, icebergs, the world's southernmost caribou herd, historic sites, a 50-metre suspension bridge, two active archaeological dig sites, and many more attractions. (Not all 25 trails are located near St. John's). https://destinationstjohns.com/explore/land/



CSTM 2025 CONFERENCE COMMITTEE MEMBERS

CSTM CONFERENCE COMMITTEE CO-CHAIRS	STANDING SCIENTIFIC COMMITTEE
Melissa Dawe	Julie Hendry
Dr. Akash Gupta	Ed Pryzdial
ST. JOHN'S CORE PLANNING COMMITTEE	Johnathan Mack Melanie Dieude
Amanda Adey	Catherine Latour
Melissa Dawe	Oksana Prokopchuk-Gauk
Akash Gupta	Akash Gupta
Sasha Hayse	Melissa Dawe
Chris Leaman	Andrew Shih
Danny Rowsell	Lianna Peruzza
CSTM SPONSORS & EXHIBITS COMMITTEE	Danny Rowsell
Sheena Scheuermann	Joanna McCarthy
	Nicole Gettle
CSTM WEBMASTER	ABSTRACTS WORKING GROUP
Jenn Danielson	Julie Hendry
REGISTRATION WORKING GROUP	Nicole Gettle
Carla Shea	Tanya Petraszko
Michele Perry	Yulia Lin
Sheila Anthony	SPEAKER MANAGEMENT WORKING GROUP
Edith Hein	
CSTM DOADD CONFEDENCE HAISON	Sasha Hayse
CSTM BOARD CONFERENCE LIAISON	Nour
Julie Hendry	Elaine Blais
Nicole Gettle	
	_

THANK YOU

The St. John's Core Planning Committee extends its sincere gratitude to the CSTM Board for allowing us to host the 2025 Annual Conference. Thank you to our committed volunteers, esteemed speakers and moderators for their invaluable contributions in making our conference a success. We are equally grateful to our sponsors, exhibitors, partners and St. John's Convention Centre staff for their support and dedication. Finally, to all attendees for travelling to St. John's, we thank you and hope you have enjoyed our beautiful city and province.



We are looking forward to seeing you next year in Hamilton!

